Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Lineage Cell Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +11 vs. Q3 2023
- Shares held
- 75.7M
- +202.5K (+0.3%) vs. Q3 2023
- Total value
- $82.5M
- −$6.58M (−7.4%) vs. Q3 2023
- New holders
- 15
- 27 more added
- Sold out
- 4
- 25 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 477,566 | $520.5K | 0.00% | +199,750+71.9% | Added |
| Nuveen Asset Management, LLC | 515,445 | $561.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 587,429 | $640.3K | 0.00% | +190,496+48.0% | Added |
| JPMorgan Chase & Co | 727,013 | $792.4K | 0.00% | +17,535+2.5% | Added |
| Bridgeway Capital Management, LLC | 781,766 | $852.1K | 0.02% | 00.0% | Unchanged |
| MAI Capital Management | 803,845 | $876.2K | 0.01% | −150,843−15.8% | Reduced |
| Northern Trust Corp | 1,195,184 | $1.30M | 0.00% | −8,773−0.7% | Reduced |
| Prescott General Partners LLC | 1,851,851 | $2.02M | 0.12% | 00.0% | Unchanged |
| State Street Corp | 2,096,609 | $2.29M | 0.00% | +73,763+3.6% | Added |
| Raffles Associates LP | 2,131,621 | $2.32M | 2.94% | +543,882+34.3% | Added |
| Geode Capital Management, LLC | 2,935,811 | $3.20M | 0.00% | +168,874+6.1% | Added |
| Defender Capital, LLC. | 4,969,675 | $5.42M | 1.90% | −214,835−4.1% | Reduced |
| Vanguard Group Inc | 8,384,687 | $9.14M | 0.00% | +72,355+0.9% | Added |
| BlackRock Inc. | 8,531,498 | $9.30M | 0.00% | −756,536−8.1% | Reduced |
| Broadwood Capital Inc | 34,935,485 | $38.1M | 3.25% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −51,220−100.0% | Sold out |
| Summit X, LLC | 0 | $0 | 0.00% | −10,925−100.0% | Sold out |
| USAdvisors Wealth Management, LLC | 0 | $0 | 0.00% | −10,869−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −7,125−100.0% | Sold out |